Results

A total of 194 matching records were found.

ACOSOGZ1031
Randomized Phase III Trial Comparing 16 or 18 Weeks of Neoadjuvant Exemestane (25mg daily) Letrozole (2.5 mg) or Anastrozole (1mg)in Post-Menopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

ACOSOGZ6041
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2uNO Rectal Cancer

E1104
A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer

E1302
Phase III Randomzied, Placebo Controlled, Trial of Docetaxel versus Docetaxel + ZD1839 in PS2 Patients or Previously-Treated patients with Recurrent or Metastatic Head and Neck Cancer

E1304
Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (VELCADE) in Combination with Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients with Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

E1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

E1602
A Randomized Phase II Trial of Multi-Epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma

E1804
Phase II Trial of Sorafenib (BAY43-9006) (IND69896; NSC 724772) in Patients with Advanced Urothelial Cancer

E1904
A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) with Subcutaneous Campath (NSC 715969) for Adults with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

E1905
A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage "

E1F05
Phase II Study of Rituximab Given in Conjunction w/Standard Chemotherapy in Primary CNS Lymphoma

E2402
A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma "

E2404
Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms

E2603
A Double-Blind Randomized, Placebo Controlled Phase III Trial of Carboplatin, Paclitaxel, and BAY 43-9006 vs. Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma

E2805
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

E3404
Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning

E3805
CHAARTED: ChemoHormonal Therapy vs. Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

E4402
Randomized Ph. III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

E5202
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

E5501
A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer(SCLC): Topotecan Squenced with Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide

E5597
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer

E5998
Phase II Study of Initial Treatment with Methotrexate in Large Granular Lymphocytic (LGL) Leukemia

ECALGB80101
Phase III Intergroup Trial of Adjuvant Chemoradition After Resection of Gastric or Gastroesophageal Adenocarcinoma

EIBCSG2402
Ph. III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer

ENCCTG0147
A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) after Curative Resection for Patients with Stage III Colon Cancer

EPACCT1
Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment: The TAILORx Trial

G0087M
A Phase II Evaluation of Trabectedin (Yondelis, R279741, IND#75,111) In The Treatment Of Advanced, Persistent or Recurrent Uterine Leiomyosarcomas

G0146O
A Ph. II Evaluation of Irofulven in the Treatment of Recurrent or Persistent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer

G0218
Phase III Trial of Carboplatin and Paclitaxel Plus Placebo vs. Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo vs. Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, In Women with Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian or Primary Peritoneal Cancer

G9916
Ph.I Trial of Intravenous Paclitaxel Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin, and Intraperitoneal Paclitaxel in Patients with Previously Untreated Epithelial Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal Carcinoma

G9917
A Dose Escalating Phase I Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin and Intravenous Paclitaxel in Patients with Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

G9918
Phase I Trial of Tailored Radiation Therapy with Concomitant Cetuximab and Cisplatin in the Treatment of Patients with Cervical Cancer

J0347
High Dose Samarium-153 with Peripheral Blood Stem Cell Support in High Risk Osteogenic Sarcoma

J0373
HLA Matched Related and Unrelated Bone Marrow Transplantation with Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide For Hematological Malignancies

J0381
A Phase I/II Partial Breast Irradiation with Concurrent Chemotherapy

J0386
Ph.II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839

J0389
A Randomized Phase II Chemopreventive Study of Iloprost Versus Placebo in Patients at High Risk for Lung Cancer

J0409
Ph. II Study of Intensified CVP, Rituximab and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma

J0412
An Open-Label Extended- Use Study of Oral CEP-701 in Patients with Hematologic Malignancies Who Have Participated in a Clinical Study of CEP-701

J0415
Phase II Clinical, Biological, and Pharmacological Study of Rapamycin (Rapamune, Sirolimus) in Patients with Advanced Pancreatic Cancer

J0423
Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood

J0425
Ph.II Study of Fixed Dose Capecitabine in Metastatic Breast Cancer

J0427
Evaluation of the Biological Effects of Broccoli Sprout Extract in Smokers

J0457
Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignances

J0459
Phase II Trial of Irinotecan in Metastatic Medullary Thyroid Cancer

J0466
A Phase I and Pharmacological Trial of 17-Allylamino-17 Demethoxygeldanamycin (17-AAG) and Cytarabine in Refractory Leukemia and Myelodysplastic Syndrome

J0473
Pharmacokinetics, Biodistribution and Targeting of 111In-Labeled Humanized PAM4 IgG in Pre-Surgical Pancreatic Cancer Patients: An Examination of Protein Dose

J0479
A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A 0201-Positive Patients with Previously Treated Uresectable Stage III or IV Melanoma

J0486
Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy

J0501
A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene in Combination with Erbitux (Cetuximab) for the Treatment of Advanced Pancreatic Adenocarcinoma

J0509
Phase I Dose Escalation Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Agent for Adult with Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crisis

J05102
A Phase II Study of Cetuximab in Combination with External Beam Radiation Followed by Consolidation Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer

J05109
A quality of life comparison in patients with malignant dysphagia treated with either self-expanding plastic stents (SEPS) or self-expanding metal stents (SEMS)

J05113
A Randomized, Ph II/III Study of TNferade Biologic with 5-FU And Radition Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

J05114
Phase I, Randomized, Multicenter, Double Blinded Study of MK-0429 in the Treatment of Men with Hormone Refractory Prostate Cancer and Metastatic Bone Disease

J05115
K562/GM-CSF Vaccination in Patients with Myelodysplastic Syndrome

J05117
A Phase I Study of Oral PHA-848125AC Given Daily for 7 Consecutive Days Every 2 Weeks or for 4 Consecutive Days a Week for 3 Consecutive Weeks Every 4 Weeks to Adult Patients with Advanced Metastatic Solid Tumors

J05118
A Feasibility Study of Combination Therapy with Trastuzumab, Cyclophosphamide and an Allogeneic GM-CSF Secreting Breast Tumor Vaccine for the Treatment of HER-2/neu-Overexpressing Metastatic Breast Cancer

J05121
A Randomized Phase II Trial of Interferon + GM-CSF versus K562/GM-CSF Vaccination in CML Patients Achieving a Complete Cytogenetic Response to Imatinib "

J0515
Ph. II Trial of PTK787/ZK222584 in Patients with Advanced or Metastatic Pancreatic Adenocarcinoma who Failed First-Line Gemcitabine Therapy

J0518
A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of Recombinant Human Lactoferrin as Prophylaxis for Chemotherapy-Induced Mucositis and Neutropenic Fever in Acute Myelogenous Leukemia Patients

J0519
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Myco0phenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination with Corticosteroids

J0528
Phase I/II Study of Rituximab, High Dose Cyclophosphamide, and GM-CSF Based Immunotherapy for Relapsed Hodgkin's Lymphoma

J0534
Phase II Study of Erlotinib Combined with Chemoradiation and Adjuvant Chemotherapy in Patients with Resectable Pancreatic Cancer

J0548
Phase I Study of Erbitux (Cetuximab) in Pediatric Subjects with Refractory Solid Tumors: Charaterization of Serum Pharmacokinetics, Safety, and Efficacy of Cetuximab when Combined with Irinotecan

J0551
Cyclophosphamide plus Transplantation of Partially HLA-Mismatched (Haploidentical), CD8+ T Cell-Depleted Peripheral Blood Cells (PBCs) for Patients with Myelodysplastic syndrome(MDS), refractory acute myeloid leukemia (AML) or Myeloproliferative Disorders (MPD)

J0554
A Phase I, Open-Label Multi-Center, Dose Escalation Study of the Safety and Pharacokinetics of AGS-PSCA Given as Monotherapy in Subjects with Advance Prostate Cancer

J0558
A Multi-Center Rand-omized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response with Aromatase Polymorphism

J0561
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias

J0563
Ex vivo Expansion of Mafosfamide Purged CD34+ cells in Patients with Acute Leukemia

J0566
A Multi-Center Phase Ib Study of Oxaliplatin in Combination with Fluorouracil and Leucovorin in Pediatric Patients with Advanced Solid Tumors

J0569
A Phase I Study of Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined with Docetaxel in Subjects with Metastatic Hormone-Refractory Prostate Cancer

J0570
Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with the VEGF Inhibitor Bevacizumab in Patients with Metastatic Renal Cell Carcinoma

J0576
A Pharmacodynamic Study of Pre-Prostatectomy Rapamycin in Men with Advanced Localized Prostate Cancer

J0581
Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients with Solid Tumors

J0590
Phase I Safety Study of Clostridium novyi-NT Spores in Patients with Treatment Refractory Solid Tumor Malignancies

J0598
Phase II Trial of Bevacizumab with Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma

J0602
Phase I/II Clincial Trial of Oral Vorinostat (MK-0683) in Combination with Erlotinib in Patients with Relapsed/ Refractory Non-Small Cell Lung Cancer

J0603
A Multicenter, Open Label, Randomized, Ph IIIComparing Immediate Adj Hormonal Therapy in Combo w/Taxotere Admin Every 3Wks vs. Hormonal Therapy Alone vs. Deferred Therapy Followed by the Same Therapeutic Options in Pts w/Prostate Ca at High Risk of Relapse After Radical Prostatectomy

J0606
Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies

J06101
Phase I, Open-label, Multi-center, Dose-Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination with Weekly Standard Dose Gemcitabine in Patients with Advanced Solid Malignancies

J06102
Revlimid to Augment Efficacy of Prevnar Vaccines in Patients with Relapsed or Refractory Myeloma

J06105
Defibrotide for the Treatment of Severe Hepatic Veno-Occulsive Disease in Hematopoietic Stem Cell Transplant Patients

J06110
Phase I S-TRANS, TRANS-FARNESYLTHIOSALICYLIC ACID Administrated on Days 1 to 21 of a 28 Cycle in Combination with Gemcitabine in Pts w/Adv Biliary Tract & Pancreatic Cancer "

J06111
A Multicenter, Open-Label, Single Agent, Two Stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects with Advanced Malignant Glioma

J06114
A Phase II Study of an Oral Histone Deacetylase Inhibitor, MS-275 in Combination with Sargramostim Treating MDS or Relapsed and Refractory Myeloid Malignancies

J06116
High Dose Cyclophosphamide in Steroid Refractory Acute Graft Versus Host Disease

J06118
Posttransplant Immunotherapy Using Donor Lymphocyte Infusions with Autologous Tumor Vaccines Following HLA Related Bone Marrow Transplantation or Hematologic Malignancies

J06122
Open-Label, Multi-Center Study of the Efficacy and Safety of MCC in the Treatment of Patients with Non-Muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who are Refractory to BCG

J06123
Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin?s Lymphoma

J06127
A Randomized Phase II Study of Docetaxel +/- ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma

J06128
A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer

J06131
Open-Label, Ph.I Study of Systemic Hedgehog Pathway Antagonist, GDC0449, In Patients with Locally Advanced or Metastatic Solid Tumors that are Refractory to Standard Therapy or For Whom no Standard Therapy Exists

J06132
Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer

J06133
Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 64890, IND 46,211) Given in Timed Sequential Combination with Cytosine Arabinioside (ara-C) and Mitoxantrone for Adults with Relapsed and Refractory Acute Leukemias

J06134
Toward Development of an Individualized ""Patient Tailored"" Approach to Pancreatic Cancer Treatment"

J06137
PHI Dose Escalation Study to Examine the Safety and Tolerability of IC83 Administered 1 Day after Pemetrexed 500 mg/m2 Every 21 Days in Patients with Cancer

J0614
A Phase I Dose Escalation Study of BMS 641988 in Patients with Castration-Resistant Prostate Cancer

J06143
KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma

J0615
Phase II trial of Rituximab-ABVD for Classical Hodgkin's Lymphoma

J0620
A Pilot Study of Differentiation Therapy in Multiple Myeloma Using Interleukin-6 and Interferon-a

J0623
Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma after Oral Administration

J0625
K562/GM-CSF Vaccination in Combination with Imatinib Mesylate as Booster for Chronic Myeloid Leukemia Patients Previously Vaccinated on Protocol J0345

J0626
Phase II Study of Mitomycin-C in Patients with Advanced or Recurrent Pancreatic Cancer with Mutated BRCA2 Gene

J0634
A randomized controlled comparative trial to determine if testosterone gel prevents steroid related weakness in brain cancer patients

J0637
A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

J0638
Phase II Trial of Triapine (IND #68338, NSC #663249, 3-aminopyridine-2-carboxaldehyde thiosemicarbone) plus Fludarabine (NSC #312887, fludarabine monophosphate) in Adults with Aggressive Myeloproliferative Disorders (MPDs)

J0644
Phase II Study of a Single-Agent Cetuximab for Treatment of High-Risk Pre-Malignant Upper Aerodigestive Lesions

J0647
Psychopharmacology of Psilocybin in Cancer Patients

J0650
Multicenter Selective Lymphadenectomy Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node

J0658
A Phase I/II Study of MS 275 in Combination with 5-azacytidine in Patients with Recurrent Advanced Non-Small Cell Lung Cancer

J0659
A Study of the Efficacy of MORab-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

J0660
Therasphere for the Treatment of Liver Metastases: Open Label Trial of Therasphere in Patients with Liver Metastases from Primary Colorectal Cancer, Neuroendocrine Cancer or Non-Colorectal/Non-Neuroendocrine Cancer

J0661
Phase I Study of Alefacept (Amevive) in Treatment of Cutaneous T-Cell Lymphoma and Peripheral T-Cell NHL

J0662
Phase I Trial of Gemcitabine (Gemzar) + ABI-007 (Abraxane) in Patients with Advanced Metastatic Pancreatic Cancer

J0663
Open Label Dose Escalation Ph. I Trial of MK-0646 Given as a One to Two Hour Every Other Week Infusion in Patients with Relapsed or Refractory Locally Advanced or Metastatic Cancers

J0669
Phase II Study of Alvocidib (NSC 649890, IND 46,211) in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias

J0676
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Paritally HLA-Mismatched Bone Marrow for Patients with Sickle Cell

J0677
Ph.I Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients with Refractory or Relapsed Solid Tumor Malignancies

J0684
A Pharmacokinetic and Pharmacogenomic Study of Patients with High-Grade Gliomas Receiving Daily Radiation Therapy and Temozolomide "

J0686
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer "

J0688
Phase 1 Safety Evaluation of Oral Enzastaurin in Combination with Bevacizumab in Patients with Advanced/Metastatic Cancer

J0698
An Open Label Ph I/II Study of XIAP Antisense AEG35156 Administered to Patients with Refractory/Relapsed AML in Combination with Chemotherapy

J0702
A Phase II Safety and Efficacy Study with the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients with Metastatic Urothelial Cancer

J0703
A Phase I/II Study of 131I-Tositumomab in Patients with Relapsed/Refractory Hodgkin?s Lymphoma

J0706
A Randomized, Open Label, Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For the Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere Containing Regimen

J07102
Phase I/II Study of Obatoclax Mesylate (GX15-070MS), a bcl-2 Antagonist, plus Topotecan in Relapsed Small Cell Lung Carcinoma

J07108
A randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer

J07109
A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818, IND #58,359) in Combination with Oral Etoposide (VP-16) in Elderly Adults with Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML

J07118
Phase 1 Open Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Oral Azacitidine I Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

J07131
Phase II, Open Label, Single Arm Study of I.V Panobinostat (LBH589) in Patients with Metastatic Hormone Refractory Prostate Cancer

J0714
A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small-Cell Lung Cancer"

J0715
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children and Young Adults with Relapsed or Refractory Acute Leukemias

J0716
A Phase Ib, Open Label, Multi-Center Trial of Intravenous INO-1001 plus oral Temozolomide to Evaluate the Tolerability, Safety, and Pharmacokinetics in Subjects with Newly-Diagnosed or Recurrent Unresectable Stage III or Stage IV Melanoma

J0718
A Phase I Open-Label Dose-Finding Study of Intravenous BI 2536 BS

J0719
An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer

J0721
A Phase 2 Study of Temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6 Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter

J0722
A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MGCD0103 (MG-0103) in Combination with Docetaxel (Taxotere) in Subjects with Advanced Solid Malignancies

J0730
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

J0741
Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin with IV Avastin Therapy in Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin

J0742
A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors

J0745
A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a GM-CSF Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer

J0749
A Phase I Investigation of the Intravenous Administration of MK-4721 in Patients with Advanced Hormone Refractory Prostate Cancer

J0758
A Phase II Trial of Dasatinib in Advanced Sarcoma

J0768
A Phase I Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Patients with Refractory or Relapsed Multiple Myeloma

J0770
Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma

J0779
Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability and Immune Response of CRS-207 in Adults Subjects with Selected Advanced Solid Tumors Who Have Failed or Who are not candidates for Standard Treatment

J0783
A Phase 1 Study of ABT-888 in Combination with Topotecan plus Carboplatin for Relapsed and Refractory Acute Leukemias and High-Risk Myelodyplasias and Myeloproliferative Disorders

J0786
Phase 1b Open-label, Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS 595 Injection in Combination with Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia

J0791
Safety and Efficacy of POMx in Men with Prostate Cancer: An 18-Month, Randomized, Double-Blind, Dose-Finding Study of the Effects of Two (2) Doses of Pomegranate Juice Extract Capsules (1 or 3 capsules/day) on Rising Prostate Specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

J0794
A PhaseI/II, Open-label, Dose Escalation, trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of RAF265 (CHIR-265) Administered Orally to Patients with Locally Advanced or Metastatic Melanoma

J0798
A Phase I/II Multi-Institutional Double Blinded Randomized Study to Determine the Tolerability ad Efficacy of 2 Different Doses of Revlimid (CC-5013, Lenalidomide) in Biochemically Relapsed Prostate Cancer Patients (M0) after Local Treatment

N0302
Pharmacokinetic Study of Methotrexate Using an Intratumoral Microdialysis Catheter

N0503
Open Label Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid in Subjects with Recurrent High Grade Glioma

N0504
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients with Recurrent Glioblastoma

N0602
A Phase I, Open Label Study of AT-101 Plus Radiotherapy and Temozolomide and of AT-101 Plus Adjuvant Temozolomide for Patients with Newly-Diagnosed Glioblastoma Multiforme

N2111
A Phase I/II Trial of BMS-247550 for Treatment of Patients with Recurrent High-Grade Gliomas

N2201
Phase II Study of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy for Patients with Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL)

N9902
Ph. I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults with Newly Diagnosed Glioblastoma Multiforme

PAALL0232
High Risk B-Precursor Acute Lymphoblastic Leukemia

PAALL0331
Standard Risk B-Precusor Acute Lymphoblastic Leukemia

PAALL0433
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

PAALL0434
Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia

PAALL0631
A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)

PAAML03P1
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML)Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study

PAAML0431
The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years

PAAML0523
A Phase I/II Study of CLOLAR? (Clofarabine, IND# 73,789) in Combination with Cytarabine in Pediatric Patients with Refractory/Relapsed Leukemia

PAAML0531
Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults

PAAML06P1
A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young Patients with Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia

PACNS0122
A Phase II Study to Assess the Ability of Neoadjuvant Chemotherapy +/- Second Look Surgery to Eliminate All Measurable Disease Prior to Radiotherapy for NGGCT

PACNS0232
Radiotherapy alone versus chemotherapy followed by response-based radiotherapy for newly diagnosed primary CNS germinoma

PACNS0331
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial "

PACNS0334
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy without Methotrexate

PADVL0221
A Phase II Study of Trabectedin in Children with Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Sarcomas

PADVL04P2
Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)

PAHOD03P1
Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD).

PAHOD0431
Ph III Study for the Tx of Children& Adolescents w/Newly Diagnosed Low-Risk HD

PANBL0531
Response and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

PANBL0532
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

PAOST0221
A Phase II Study of Aerosolized GM-CSF in Patients with First Pulmonary Recurrent of Osteosaroma

PAOST0331
Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy

PARAR0331
Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy

PAREN0321
Treatment of High Risk Renal Tumors

PAREN0532
Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor

PAREN0533
Treatment for Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor

PARET0332
A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy

PARST0331
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

PARST0332
Risk-Based Treatment of Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas-- Groupwide Phase III Study

PARST0431
Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma

PARST0531
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)"

PASCT0431
A Randomized Trial of Sirolimus-Based Graft versus Host Disease (GVHD) Prophylaxis after Hematopoietic Stem Cell Transplantation (HSCT) in Relapsed Acute Lymphoblastic Leukemia (ALL)

PASCT0521
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute, Non-infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation

PASCT0631
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation

R0413
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0,I,or II Breast Cancer